Trkulja, V. (2023). Why we should not recommend or offer fluvoxamine to COVID-19 patients?. European Journal of Clinical Pharmacology, 79. (2), 321-322. doi: 10.1007/s00228-022-03447-3
Trkulja, Vladimir. "Why we should not recommend or offer fluvoxamine to COVID-19 patients?." European Journal of Clinical Pharmacology, vol. 79, no. 2, 2023, pp. 321-322. https://doi.org/10.1007/s00228-022-03447-3
Trkulja, Vladimir. "Why we should not recommend or offer fluvoxamine to COVID-19 patients?." European Journal of Clinical Pharmacology 79, no. 2 (2023): 321-322. https://doi.org/10.1007/s00228-022-03447-3
Trkulja, V. (2023) 'Why we should not recommend or offer fluvoxamine to COVID-19 patients?', European Journal of Clinical Pharmacology, 79(2), pp. 321-322. doi: 10.1007/s00228-022-03447-3
Trkulja V. Why we should not recommend or offer fluvoxamine to COVID-19 patients?. European Journal of Clinical Pharmacology [Internet]. 2023 February [cited 2024 August 30];79(2):321-322. doi: 10.1007/s00228-022-03447-3
V. Trkulja, "Why we should not recommend or offer fluvoxamine to COVID-19 patients?", European Journal of Clinical Pharmacology, vol. 79, no. 2, pp. 321-322, February 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:779915. [Accessed: 30 August 2024]